Synairgen plc - Grant of Options

RNS Number : 4597T

Synairgen plc

15 November 2023

Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 14 November 2023 the Board of Synairgen granted options ('Options') over 1,900,000 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.94 per cent. of the Company's issued share capital.

Following this grant, Synairgen has 18,940,446 options in issue, representing 9.41 per cent. of the Company's issued share capital.

Certain Options were issued to the recently recruited Chief Financial Officer and Chief Medical Officer respectively, the former a Director of the Company; the later a Persons Discharging Managerial Responsibilities ('PDMR'):

	Options issued 14 Nov 2023	Total options	Ordinary shares	Total interest	Percentage holding of fully diluted share capital
Directors
Joseph Colliver	750,000	750,000	-	750,000	0.34%
PDMRs
Marcin Mankowski	750,000	750,000	-	750,000	0.34%

The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 13 November 2033, subject to the achievement of appropriate performance criteria which match the criteria for the 2022 award as set out on page 23 of the 2022 annual report.

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Joseph Colliver
2.	Reason for notification
a)	Position / status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	750,000 Options awarded Exercise price of one pence
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	14 November 2023
f)	Place of the transaction	Outside a trading venue

1.	Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)	Name	Dr Marcin Mankowski
2.	Reason for notification
a)	Position / status	Chief Medical Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Synairgen plc
b)	LEI	213800IMMTOPPDF8HD24
4.	Details of the transaction(s):
a)	Description of the financial instrument Identification code	Options over ordinary shares of 1p each GB00B0381Z20
b)	Nature of the transaction	Award of Options under the Company's share plans
c)	Price(s) and volume(s)	750,000 Options awarded Exercise price of one pence
d)	Aggregated information Aggregated volume Price	n/a
e)	Date of the transaction	14 November 2023
f)	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAEFLFEADFAA]]>